tbuckley/cabot-search huggingface dataset:
Primary care providers propensity to order non-recommended surveillance testing after curative breast cancer treatment.
Authors: Lauren P. Wallner, Paul Abrahamse, Archana Radhakrishnan, Ann S. Hamilton, Kevin C. Ward, Sarah T. Hawley, Steven J. Katz
Journal: Journal of Clinical Oncology (2019)

52 Background: Team-based cancer care models promote primary care providers taking on a larger role in survivorship care. However, little is known about PCP attitudes toward and propensity to order non-recommended surveillance testing. Methods: A stratified random sample of PCPs identified by early-stage breast cancer patients diagnosed in 2013-15 who participated in iCanCare Study (Georgia and Los Angeles SEER registries) were surveyed about their experiences caring for cancer patients (N = 519, 58% response rate). PCPs were asked in a clinical vignette whether they would order non-recommended bone scans, other imaging (i.e. PET) or tumor marker testing (i.e. CA-125) in an asymptomatic, early-stage breast cancer survivor. A composite score was created by averaging their responses to the individual items, and categorized by tertiles into low, selective and high propensity to order non-recommended testing. PCP confidence in their knowledge about appropriate testing was also measured (5 pt. Likert-type scale; not all all-very confident) and compared with propensity to order. Multivariable, weighted, multinomial logistic regression was used to then evaluate PCP-reported factors associated with high and selective propensity to order non-recommended testing (vs. low). Results: In this sample, 32% of PCPs had a low propensity, 40% selective, and 28% a high propensity to order non-recommended surveillance tests. Of the 80% of PCPs who reported they were confident in their knowledge about appropriate testing, 27% had a high propensity to order. PCPs practicing in staff-model HMOs were less likely to have a high or selective propensity to order (vs. low) when compared to PCPs in private practice. (high aOR: 0.4, 95%CI: 0.2-0.7; selective aOR: 0.3, 95%CI: 0.2-0.6). Conclusions: Over a quarter of PCPs had a high propensity to order non-recommended surveillance testing for early-stage breast cancer patients, yet the majority reported they were confident in their knowledge about appropriate surveillance testing. Efforts to increase PCP knowledge about the specifics of breast cancer surveillance may be warranted to reduce the overuse of non-recommended testing during survivorship.
Exploratory analysis of the cost of episodes of care in metastatic renal cell carcinoma in the United States.
Authors: Anne Kangethe, Michael Polson, Lindsay C. Speicher, Ying Zheng, Abhijeet Bhanegaonkar, Stan Krulewicz, Ruth Kim
Journal: Journal of Clinical Oncology (2019)

55 Background: Treatment decisions in oncology care have financial implications. A shift in reimbursement from traditional fee-for-service models toward episode-based care sets the framework for assessing the value of therapies. The objective of this study was to determine episode-based total cost (medical and pharmacy) and resource utilization by therapy for patients with metastatic renal cell carcinoma (mRCC) using the Oncology Care Model methodology. Methods: Retrospective analysis of commercial claims data incurred between Jan 1, 2013 and Jun 30, 2018. Patients included had ≥1 claim with a diagnosis code of renal cell carcinoma (RCC), ≥2 claims for metastasis on or after initial RCC diagnosis date, evidence of any mRCC systemic therapy on or after initial mRCC diagnosis date, and continuous enrollment from ≥6 months before until ≥6 months after the index date and were ≥18 years old on the index date. Patients were classified by 1 of 6 therapy classes: tyrosine kinase inhibitors (TKIs) monotherapy, mechanistic target of rapamycin (mTOR) monotherapy, immuno-oncology (IO) monotherapy, other (e.g., interferon) monotherapy, changed therapy class (e.g., from TKI to mTOR), or traditional chemotherapy. Results: 606 commercially insured patients with mRCC met the inclusion criteria. Most received monotherapy, and 53% had ≥2 episodes. Specifically, 59% of TKI, 17% of mTOR, 28% of IO, 59% of other, 85% of changed therapy class, and 38% of chemotherapy patients had ≥2 episodes. IO patients had the longest average inpatient length of stay per episode (7 days; p = 0.0002). There were differences in total episode costs among each selected therapeutic class: TKI (n = 161; $61,417), mTOR (n = 30; $67,637), IO (n = 75; $92,082), other (n = 34; $98,877), changed therapy (n = 130; $84,480), and chemotherapy (n = 34; $55,743) (p &lt; 0.0001). Conclusions: Differences in total episode costs exist in each monotherapy class used to treat mRCC, even in an episode-based structure. As healthcare financing shifts to alternative payment models, it is important to investigate overall episode cost of care for various therapies, as the cost for the individual drug may not accurately reflect the total episode value.
Abstract 242: Sk Channels in the Vascular Endothelial Cells
Authors: Young Woo Nam, Taibah Aldakhil, Adam Viegas, Hannah Vu, Rachel Lee, Pammie Wong, Miao Zhang
Journal: Circulation Research (2019)

Small-conductance Ca 2+ -activated K + (SK) channels are a unique group of K + channels, that play important roles in the vascular system and central nervous system. Four subtypes in the SK channel family are encoded by KCNN mammalian genes: including KCNN1 for SK1 (K Ca 2.1), KCNN2 for SK2 (K Ca 2.2), KCNN3 for SK3 (K Ca 2.3) and KCNN4 for SK4 (also IK or K Ca 3.1) channels. It is well known that the activation of SK channels expressed on the endothelial cell surface can reduce vascular tone. In our study, we found that SK channels expressed on the endoplasmic reticulum (ER) membrane can protect endothelial cells from apoptosismediated by ER stress. Among the four subtypes of SK channels, Ca 2+ sensitivity and subcellular localization significantly varies by subtype in endothelial cells. Ca 2+ sensitivity of the SK1 channel subtype is negatively modulated more than that of the SK2 subtype, whereas the cell surface expression of the SK2 channel subtype is negatively modulated more than that of the SK1 subtype. The functions of SK channels to reduce vascular tone and to protect against apoptosis are greatly affected by their Ca 2+ sensitivity and subcellular localization. It is critical to understand how each SK channel subtype is modulated, which may become promising therapeutic targets for various cardiovascular conditions.
Risk factors for healthcare utilization in patients with newly diagnosed advanced lung cancer.
Authors: Emily Miller Ray, Sharon Peacock Hinton, Katherine Elizabeth Reeder-Hayes
Journal: Journal of Clinical Oncology (2019)

111 Background: Advanced lung cancer (ALC) is a symptomatic disease often diagnosed in the context of hospitalization. The index hospitalization may be a window of opportunity to improve care delivery. We aimed to identify newly diagnosed ALC patients at highest risk for subsequent healthcare utilization. Methods: We identified patients in SEER-Medicare with: ALC (stage IIIB-IV SCLC or NSCLC), diagnosed 2007-13; continuous enrollment -6 months from diagnosis through death or 12/2014; and an index hospitalization within 7 days of ALC diagnosis. Our primary outcomes were 30-day re-hospitalization and emergency department (ED) use. We used a time-to-event model with multivariate regression to identify risk factors. Results: Of ALC patients in SEER-Medicare, 54% (n=28,976) had an index hospitalization. Of those who survived to discharge, by 6 months, 47% had been re-hospitalized, and 50% had enrolled in hospice. Only 37% of patients ever received systemic treatment for their cancer, and the median time to treatment was 46 days. The 30-day ED visit and readmission rates were 13% and 35%, respectively. Pre-cancer ED use or hospitalization, SCLC, and prolonged length of stay were associated with higher risk of 30-day utilization. Palliative care consultation and discharge to hospice were associated with substantially lower risk of 30-day readmission. Conclusions: Many newly diagnosed ALC patients experience an early return to the hospital. These patients may benefit from increased access to palliative and other supportive care during index hospitalization to prevent subsequent healthcare utilization. [Table: see text]
Synthetic De Novo Modeling of Human T-Cell Acute Lymphoblastic Leukemia Reveals HOXB Genes Drive Expansion of Leukemia Cells-of-Origin and Established Tumor Clones
Authors: Manabu Kusakabe, Ann Chong Sun, Kateryna Tyshchenko, Rachel Wong, Aastha Nanda, Claire Shanna, Samuel Gusscott, Elizabeth Chavez, Alireza Lorzadeh, Alice Zhu, Ainsleigh Hill, Stacy Hung, Scott Brown, Artem Babaian, Xuehai Wang, Robert Holt, Christian Steidl, Aly Karsan, R. Keith Humphries, Connie J. Eaves, Martin Hirst, Andrew P. Weng
Journal: Blood (2018)
Can PET CT predict response in locally advanced rectal cancer patients treated with induction FOLFOX?
Authors: Seyda Gunduz, Hasan Senol Coskun, Sema Sezgin Goksu, Deniz Arslan, Ali Murat Tatli, Mukremin Uysal, Burhan Savas, Mustafa Ozdogan
Journal: Journal of Clinical Oncology (2013)

e14696 Background: The aim of this study was to determine the pathological complete response rates in a group of locally advanced rectal cancer patients who underwent chemoradiotherapy after treatment with induction FOLFOX chemotherapy and the relationship between the complete response and Positron emission tomography - computed tomography (PET-CT). Methods: The files of 239 patients who were diagnosed with rectal cancer between January 2008 and January 2012 were evaluated retrospectively. Of these, there were 24 locally advanced rectal cancer patients who met the following criteria: they were administered chemoradiotherapy after receiving four courses induction oxaliplatin, folinic acid and 5-Florouracil (FOLFOX) and they underwent PET-CT for staging and for the evaluation of their response to FOLFOX treatment. Of these 24 patients, 20 operable patients were included in the study. Results: The pathological complete response was obtained in 7 patients (35%) who were operated on, and then given induction four courses FOLFOX chemotherapy and chemoradiotherapy. We determined that age, gender, clinical stage at diagnosis, and PET-CT before and after induction chemotherapy were not predictive of the pathological complete response to tumor fluorodeoxyglucose (FDG) uptake activity. Conclusions: The rates of pathological complete response were increased in locally advanced rectal cancer patients who underwent short-term induction chemotherapy. Although the PET-CT has retained its importance in predicting pathological complete response, there is still a need for studies with a larger number of patients and long-term follow-ups.
Osteoclast Stimulatory Transmembrane Protein (OCSTAMP) mRNA Levels and Clinical Variables in Persons with Plasma Cell Myeloma
Authors: Ya-Lan Zhou, Jin Lu, Robert Peter Gale, Shen-Miao Yang, Li-Xin Wu, Jin-Lan Li, Ya-Zhen Qin, Yan-Rong Liu, Hao Jiang, Qian Jiang, Xiaohui Zhang, Lan-Ping Xu, Kai-Yan Liu, Xiao-Jun Huang, Guorui Ruan
Journal: Blood (2018)
Prospective National-Base Multicenter Study to Standardize the Follow-up of Type 1Gaucher Disease Patients Treated with Eliglustat Under Standard of Care Practice. Trazelga Project
Authors: Marcio M Andrade-Campos, Jorge J Cebolla, Laura Lopez de Frutos, Pilar Irun, Soledad Noya, Santiago Nieto, Lucia Villalon, Ana I Arribas, Abelardo Barez, Javier Garcia-Frade, Maria Lourdes Hermosin, Jesús-María Hernández-Rivas, Daiana Ibarretxe, Maria L Lozano, Teresa Molero, Maria Angeles Perez-Saenz, Jesus Villarrubia, Pilar Giraldo
Journal: Blood (2018)
Abstract 218: Pathophysiological Significance of Browning of Perivascular Adipose Tissue in the Development of Atherosclerosis
Authors: Yusuke Adachi, Kazutaka Ueda, Kaoru Ito, Eiki Takimoto, Issei Komuro
Journal: Circulation Research (2019)

Background: Perivascular adipose tissue (PVAT) possibly plays a pivotal role in the development of atherosclerosis through its direct local action to the vessels. However, its physiological and molecular mechanisms are less understood. Visceral and subcutaneous white adipose tissues exert a brown adipose tissue-like phenotype under specific conditions such as cold exposure, i.e. browning. We here investigated the pathophysiological role of browning of PVAT against the development of atherosclerosis after endovascular injury. Methods and Results: Endovascular injury was generated by wire insertion into the femoral artery of C57BL/6 female mice. Transcriptome analysis revealed robust upregulation of brown adipose tissue markers such as Ucp1 , Elovl3 , Cox8b and Cidea in injured arteries. Notably, administration of an atheroprotective agent, 17-beta estradiol, significantly inhibited these changes; Ucp1 was the most down-regulated gene by 17-beta estradiol administration in the entire gene set (log2-fold change = -6.58, false discovery rate = 0.003). Consistently, the upregulation of browning markers after endovascular injury and these inhibitions by 17-beta estradiol were confirmed in PVAT by quantitative real-time PCR, western blot and immunohistochemical staining. The present study also demonstrated that vascular injury promotes macrophage infiltration in PVAT accompanied with upregulation of inflammatory cytokine production. Furthermore, we confirmed spatiotemporal synchronicity between browning and inflammation in PVAT by immunohistochemical staining. Conclusions: We observed that endovascular injury elicits browning in PVAT accompanied with exacerbated inflammation, and that atheroprotective 17-beta estradiol strongly inhibits this phenomenon. These findings may provide novel insights into pathogenesis of the atherosclerosis.
Allogeneic Stem Cell Transplantation for Patients with Acute Leukemia Transformed from Myelofibrosis
Authors: Stefan O Ciurea, Marcos De Lima, Sergio Giralt, Muzaffar H. Qazilbash, Amin Alousi, Partow Kebriaei, Issa F. Khouri, Paolo Anderlini, Borje Andersson, Chitra Hosing, Srdan Verstovsek, Hagop Kantarjian, Richard Champlin, Uday Popat
Journal: Blood (2008)
Results Of a Phase 1 Study Of Quizartinib (AC220, ASP2689) In Combination With Induction and Consolidation Chemotherapy In Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
Authors: Jessica K Altman, James M. Foran, Keith W. Pratz, Denise Trone, Guy Gammon, Jorge E. Cortes, Martin S Tallman
Journal: Blood (2013)
Recurrent Stroke: The Role of Thrombophilia in a Large International Pediatric Stroke Population
Authors: Gabrielle Deveber, Fenella Jane Kirkham, Kelsey Shannon, Leonardo R. Brandao, Ronald Sträter, Gili Kenet, Hartmut Clausnizer, Mahendranath Moharir, Martina Kausch, Rand Askalan, Daune MacGregor, Monika Stoll, Antje Torge, Nomazulu Dlamini, Vijeya Ganesan, Mara Prengler, Jaspal Singh, Ulrike Nowak Goettl
Journal: Blood (2018)
Long-Term Effect of Mesenchymal Stromal Cell Derived Extracellular Vesicles on the Restoration of Engraftment of Stem Cells in Radiation Exposed Mice
Authors: Sicheng Wen, Laura R Goldberg, Mark S Dooner, Mandy Pereira, Michael Del Tatto, Elaine Papa, Yan Cheng, Peter J. Quesenberry
Journal: Blood (2018)
ENRICH: Validating a multidimensional patient-reported financial toxicity measure.
Authors: Grace L. Smith, Robert Joseph Volk, Lisa M Lowenstein, Susan K. Peterson, Alyssa G. Rieber, Cristina Checka, Kaitlin M. Christopherson, Reshma Jagsi, Sharon H. Giordano, Tito R. Mendoza
Journal: Journal of Clinical Oncology (2019)

153 Background: Financial toxicity is a patient-reported outcome reflecting burdens of cancer treatment costs. There is a need to assess financial toxicity in cancer care, as its unique domains—upstream factors like direct medical costs or downstream economic impact like bankruptcy—predict worse QOL, adherence, and mortality. Socioeconomically disadvantaged patients bear disparate financial toxicity burdens. We thus developed and report performance of a new measure, the Economic StraiN and Resilience in Cancer (ENRICh), to assess all financial toxicity domains in economically diverse patients. Methods: We studied 238 patients with Stage I-IV cancer from a tertiary academic comprehensive cancer center (MDA) and county safety-net hospital serving socioeconomically disadvantaged patients (LBJ). Financial toxicity domains and corresponding subscales were developed from qualitative/cognitive (n = 104) interviews. ENRICh and Comprehensive Score for Financial Toxicity (COST) questions were administered (n = 127; MDA = 71, LBJ = 56). To demonstrate known-group validity, we compared ENRICh scores between centers; for concurrent validity, we correlated ENRICh and COST; for reliability, we calculated Cronbach's coefficient α for ENRICh subscales (range 0, none, to 10, high burden). Results: There were 4 distinct, valid financial toxicity domains/subscales: 1) Burden of cost; 2) Disruption of financial stability; 3) Depletion of financial coping; 4) Depletion of instrumental coping. Patients from the 2 centers significantly differed in subscale and overall ENRICh scores. Socioeconomically disadvantaged patients had worse mean scores (4.9 vs 2.1, 95%CI -3.6,-2.1, effect size 1.4, P &lt; .001). ENRICh significantly correlated with COST (r = -0.82, 95%CI -0.87,-0.77, P &lt; .001). Subscales were reliable with excellent internal consistency (Cronbach α = 0.78 to 0.94). The 4 ENRICh domains collectively had synergistic impact on overall financial toxicity burden. Conclusions: ENRICh is valid, reliable, and identifies and 4 novel domains of financial toxicity. Future utility of this tool is to guide assessment/interventions targeting financial toxicity domains affecting diverse cancer patients, to mitigate disparities.
MiR-193a Is a Negative Regulator of Hematopoietic Stem Cells and Promotes Anti-Leukemic Effects in Acute Myeloid Leukemia
Authors: Kathrin Krowiorz, Raj Bhayadia, Razan Jammal, Caroline Pabst, Nicole Pochert, Christoph Rueß, Christina Miller, Konstanze Döhner, Tobias Maetzig, Hartmut Döhner, Lars Bullinger, Stephan Emmrich, Dirk Heckl, Vera Martins, Reinhild Rösler, Sebastian Wiese, R. Keith Humphries, Arefeh Rouhi, Jan-Henning Klusmann, Florian Kuchenbauer
Journal: Blood (2018)
Abstract 641: <i>Drosophila</i> Adipogenesis Regulates Cardiac Function
Authors: Laura P Musselman, Bryon F Tuthill
Journal: Circulation Research (2019)

High-calorie diets are associated with obesity, type 2 diabetes, and cardiovascular disease. Recently, several investigators have proposed a model of "maximum adipose expandability," where the limited ability of animals to store fat as triglycerides results in cellular toxicity via fatty acid overflow into alternative fates, or lipotoxicity. Tissue-specific loss-of-function studies targeting metabolic pathways in the Drosophila fat storage organ, the fat body, were used to determine the relationship between fat body lipogenesis and cardiac physiology. Our data support a model where when caloric excess overwhelms fat body lipid storage capacity, cardiac lipotoxicity ensues. Metabolomics studies in hearts and blood from these animals may help us to identify specific lipotoxins that are “conserved” between flies and humans.
Abstract 492: Adipolin/C1q/Tnf-related Protein 12 reduces Neointimal Formation And Atherosclerotic Lesion Development By Modulation Of Macrophage Inflammatory Response And Endothelial Cell Function
Authors: Koji Ohashi, Hayato Ogawa, Takashi Enomoto, Naoya Otaka, Toyoaki Murohara, Noriyuki Ouchi
Journal: Circulation Research (2019)

Objectives: Obesity is causally linked to the progression of vascular disorders including atherosclerosis and post-angioplasty restenosis. Recently, we identified adipolin/C1q/Tnf-related protein 12 as an insulin sensitizing adipokine,which is downregulated in rodent models of obesity. Here, we investigated whether adipolin modulates the development of vascular diseases using loss-of-function genetic manipulations. Methods and Results: Under basal conditions, no significant differences were observed in body weight, organ weights, blood pressure and fasting plasma glucose levels between wild-type (WT) and adipolin-knockout (APL-KO) mice. APL-KO mice exhibited enhanced neointimal thickening after femoral artery injury compared with WT mice, which was accompanied by increased expression levels of pro-inflammatory mediators including tumor necrosis factor (TNF)-α and interleukin (IL)6 in injured vessels. Conversely, systemic administration of adipolin to WT mice using adenoviral vector expression systems ameliorated injury-induced neointimal thickening and inflammatory response. APL-KO mice also showed impaired re-reendothelialization after vascular injury compared with WT mice. Furthermore, adipolin deficiency increased atherosclerotic lesion area in an apolipoprotein E-knockout mouse model, which was accompanied by enhanced inflammatory response in the arterial vessel walls. Treatment of cultured macrophages with recombinant adipolin protein attenuated lipopolysaccharide-stimulated expression of inflammatory mediators, such as TNF-α and IL6. The anti-inflammatory actions of adipolin in macrophages were reversed by inhibition of transforming growth factor-β receptor II (TGF-βRII)/Smad2 signaling. In addition, treatment of human umbilical vein endothelial cells with adipolin protein promoted migratory activity and reduced serum starvation-induced apoptosis. Conclusion: These data suggest that adipolin suppresses injury-induced neointimal formation and atherosclerosis development through its abilities to modulate macrophage inflammatory responses and endothelial cell functions in vascular walls.
Health-Related Quality of Life (HRQoL) in Patients (Pts) with Chronic Immune Thrombocytopenic Purpura (ITP): Results from Two Placebo-Controlled Phase 3 Studies of AMG 531.
Authors: James N. George, Roger Lyons, Francis J. Cuevas, Ronald S. Go, David H. Henry, Robert L. Redner, Lawrence Rice, Martin R. Schipperus, Susan D. Mathias, Sue Gao, Matthew Guo, Janet L. Nichol
Journal: Blood (2007)
Retrospective Analysis Of The Recent Treatment Strategies For The Patients With Myeloma-Related Diseases Registered In Kansai Myeloma Forum
Authors: Hirokazu Tanaka, Satoru Kosugi, Toru Kida, Kensuke Ohta, Ryosuke Yamamura, Hirohiko Shibayama, Takae Kohara, Hitomi Kaneko, Shin-ichi Fuchida, Masayuki Kobayashi, Kazue Miyamoto, Maki Shindo, Junya Kuroda, Nobuhiko Uoshima, Yayoi Matsumura, Yumi Yoshii, Yuri Kamitsuji, Shogen Boku, Kazuyoshi Ishii, Mitsuhiro Matsuda, Takayuki Takahashi, Tsuneyoshi Hamada, Yoko Adachi, Eiji Nakatani, Shosaku Nomura, Masafumi Taniwaki, Akifumi Takaori, Chihiro Shimazaki, Mitsuru Tsudo, Masayuki Hino, Itaru Matsumura, Yuzuru Kanakura
Journal: Blood (2013)
The Vascular Disrupting Agent CA4P Improves the Antitumor Efficacy of CAR-T Cells in Preclinical Models of Solid Human Tumors
Authors: Changwen Deng, Jingjing Zhao, Shixin Zhou, Jiebin Dong, Jixiang Cao, Junshuang Gao, Yun Bai, Hongkui Deng
Journal: Molecular Therapy (2019)